// startup autopsy
CMP Therapeutics
Carbohydrate science promised a new path in oncology — the capital ran out first.
marketfitSilent Shutdown
Quiet closure with no public announcement · Fatal mistake: Failed to generate compelling enough clinical data to attract pharma licensing partners or Series B investors before funding was exhausted.
Key Events Timeline
FOUNDING
CMP Therapeutics founded in the UK to develop carbohydrate-mimetic compounds for oncology applications.
FUNDING
Raised early-stage funding to advance preclinical and early clinical research programmes.
FUNDING
Final funding round of approximately $7.7M total raised; intended to fund Phase I/II clinical work.
PIVOT
Pipeline reprioritised as lead compound showed insufficient efficacy signals; sought licensing deals without success.
SHUTDOWN
CMP Therapeutics wound down operations after failing to raise further capital or secure a licensing or acquisition deal.